Elligo Health Research has unveiled new IntElligo Research Stack clinical technology designed to be used as an eSource documentation tool at the company’s study sites.
The new technology enables remote monitoring as well as management of finances, reports and analytics in real-time across sites. It is intended to save time and preserve data integrity by eliminating the need for transcription.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
IntElligo Research Stack powers the System of Accelerated Research (SOAR) model which is expected to allow direct data from source to submission, in turn boosting patient access and improving efficiency.
Elligo Health Research chief information officer Jacylyn Bodmer said: “We are improving data quality while relieving administrative burden at the research site and enabling more patient-centric interactions. IntElligo also facilitates remote monitoring, which results in faster source data verification and financial payments to our physicians.”
Bodmer added that the platform can be set up within hours based on the study protocol and can be easily integrated into the workflow at any physician’s office.
Elligo Health Research chief scientific officer Rebecca Kush said: “IntElligo bridges health care and research, leveraging global industry standards from the start (CDISC PRM and CDASH), thus facilitating aggregation and tabulation into CDISC SDTM, the required format for regulatory eSubmissions to the FDA and Japan’s PMDA.”
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataEarlier this month, the company raised $20m in a series C funding to further boost physician and patient access to clinical trials using its Goes Direct approach and IntElligo technology.
The company works to connect clinical experts with research infrastructure in order to offer an improved clinical trial solution.
